动脉网独家获悉，中国广州和美国圣路易斯 – 2025年1月21日，安炎达医药（“安炎达”或“公司”），一家专门针对免疫炎症领域的临床阶段的创新药研发公司，宣布完成由高创溪创投独家领投的数千万元人民币Pre-A轮融资。本轮融资款项将主要用于支持安炎达核心管线即MAX-001在中国/澳大利亚治疗晚期难治性实体肿瘤的首次人体临床试验。
安炎达医药成立于2022年，是一家位于广州的临床阶段的生物医药技术公司，聚焦于开发针对免疫炎症领域的创新药，以治疗癌症、疼痛、神经系统疾病和骨关节炎等多种疾病。公司科学团队相信，组织微环境决定了机体免疫系统如何对其周围环境做出反应，细胞外基质的微小变化都可能导致免疫/炎症反应过度反应或反应不足，从而导致疾病发生发展。公司的药物即专门针对组织微环境中的关键机制和途径，旨在纠正这种病理状态下的免疫炎症反应。
目前，安炎达医药公司产品组合中有 4 种临床候选药物正在开发中；另外，公司临床前药物发现部门也正在针对各种基于关键免疫炎症的靶点合成及鉴定新化合物。
安炎达医药创始人兼首席执行官 Micky D. Tortorella 表示：“肿瘤微环境中高浓度的前列腺素E2（PGE2）已引起学术界和制药工业界的注意，这是一类经由肿瘤细胞高表达的COX-2酶产生的代谢物，通过与多种类型免疫细胞的细胞膜表面GPCRs（EP1、EP2、EP3和/或EP4）结合，其可显著压制机体免疫系统对抗肿瘤的能力，这是肿瘤免疫逃逸的重要原因，也是免疫检查点抑制剂广泛耐药的关键因素。公司首发管线即MAX-001是具备全新化学骨架的新一代高选择性COX-2抑制剂，在较低剂量水平即可显著降低肿瘤微环境中的PGE2水平，进而恢复机体正常免疫功能。在数项关键理化/药化参数上，MAX-001显著优于老一代COX-2抑制剂如塞来昔布，我们认为MAX-001是全球唯一有潜力应用于泛瘤种治疗的选择性COX-2抑制剂，公司期待早日将MAX-001联合免疫检查点抑制剂推向晚期肿瘤关键临床测试阶段。我们由衷感谢高创溪创投对安炎达的大力支持和信心，我们也诚挚欢迎更多投资者与安炎达同仁一道合作，加速相关创新药转化开发。”
高创溪创投陈龙辉博士表示：“PD-1/L1抗体药物为代表的免疫检查点抑制剂已成为多种晚期实体肿瘤的前线/标准疗法，且制药工业界正大规模针对免疫细胞表面其他靶点如CTLA-4、Lag-3、Tim-3和Tigit等开发下一代肿瘤免疫药物；另外，T细胞衔接器（TCE）疗法和T细胞过继疗法（包括CAR-T、TCR-T和TIL等）在实体肿瘤中显示出广阔的治疗前景。然而，这些疗法受到肿瘤微环境中高浓度PGE2的负面调节。因此，‘清扫’肿瘤微环境中PGE2将可能极大释放以T细胞为核心的肿瘤免疫疗法的治疗潜力。我们很高兴看到安炎达MAX-001在多项临床前关键参数测试上显示其具备此类潜力，我们也期待MAX-001可以早日进入关键临床测试阶段。”
InflamaX Pharmaceuticals Announces a Succesful Pre-A Financing
Guangzhou, China (& Saint Louis, United States). January 21st, 2025 - InflamaX Pharmaceuticals ("InflamaX" or the "Company"), a clinical-stage, innovative drug research and development company specializing in the field of immuno-inflammation, announces today the completion of series Pre-A investment of tens of millions of RMB, exclusively led by GCX Ventures. This round of financing will be used to support the fist human clinical trials of MAX-001, one of InflamaX's core products for the treatment of difficult to treat solid tumors. Clinical trials to be conducted in China and Australia.
Micky D. Tortorella, Founder and CEO of InflamaX Pharmaceuticals, stated: "The high concentrations of prostaglandin E2 (PGE2) found in the tumor microenvironment has attracted a lot of attention by academic researchers and the pharmaceutical industry. PGE2 is a metabolite produced by the COX-2 enzyme, which is highly expressed in tumor cells. By binding to G protein-coupled receptors (GPCRs), including EP1, EP2, EP3, and/or EP4, found on the surface of various types of immune cells, PGE2 can significantly suppress the immune system's ability to fight tumors. This is a primary reason why tumors escape the immune system and is a key factor for the resistance to immune checkpoint inhibitors observed in many patients. Our lead candidate MAX-001 is a next-generation, selective COX-2 inhibitor with a novel chemical scaffold. At low concentrations, the drug can significantly reduce PGE2 levels in the tumor microenvironment, restoring proper immune function. In our opinion, MAX-001 is the only selective COX-2 inhibitor that can be used universally for cancer therapy because it possesses several key physicochemical properties not found in the older COX-2 drugs like Celebrex. We look forward to advancing MAX-001 into clinical trials in combination with immune checkpoint inhibitors for PD-1 resistant cancers. We sincerely thank GCX Ventures for their strong support and confidence in InflamaX. We also warmly welcome more investors to collaborate with InflamaX to accelerate the development and translation of our innovative pipelines of drugs."
Dr. Longhui Chen from GCX Ventures commented: "Immune checkpoint inhibitors, represented by PD-1/L1 antibody drugs, have become frontline/standard therapies for many advanced solid tumors. The pharmaceutical industry is also actively developing next-generation cancer immunotherapies targeting other immune cell surface targets, such as CTLA-4, Lag-3, Tim-3, and Tigit. Additionally, T cell engager (TCE) therapies and T cell adoptive therapies (including CAR-T, TCR-T, and TIL) have shown broad therapeutic potential in solid tumors. However, these therapies are negated in many patients due to the high concentration of PGE2 in the tumor microenvironment. Therefore, 'cleansing' of PGE2 from the tumor microenvironment could significantly unleash the therapeutic potential of T cell-centric cancer immunotherapies. We are pleased to see that InflamaX's pioneering asset, MAX-001, has demonstrated such potential in multiple preclinical key parameter tests, and we look forward to MAX-001 advancing into critical clinical testing stages as soon as possible."
About InflamaX
Founded in 2022, InflamaX is a clinical-stage biotechnology company located in Guangzhou that specializes in making new medicines that target immuno-inflammation as a means for treating various diseases including cancers, pain, neurological diseases and osteoarthritis. It is our belief that the tissue microenvironment determines how the immune system responds to its surrounding environment. Small changes in the extracellular matrix can cause an over-reaction or under-reaction in the immune/inflammatory response resulting in disease. Our drugs target key mechanisms and pathways in the tissue microenvironment that correct this incorrect immune/inflammatory response. We currently have 4 clinical candidate drugs in our portfolio and also have a preclinical drug discovery arm that is making new compounds against various immuno-inflammation based targets.
如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。
近
期
推
荐
声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。
动脉网，未来医疗服务平台
